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needed in constipated patients to confirm these preliminary 
data. Due to the low caloric content of yacon, the root could 
be a useful treatment in constipated diabetics or obese pa-
tients.  Copyright © 2008 S. Karger AG, Basel 
 Introduction 
 Yacon is a scientifically little known root crop taxo-
nomically classified under the Asteraceaea family that is 
native to the Andean region  [1, 2] . It is cultivated up to a 
height of 3,200 m above sea level and consumed since pre-
Inca times. Interest in this crop has increased as it is a 
plant source with the largest content of fructooligosac-
charides (FOS). Yacon was recently introduced to several 
different regions with varying climates: Brazil, Czech Re-
public, China, Korea, Japan, New Zealand, Russia, Tai-
wan and the United States  [1, 2] . Yacon is well tolerated 
with no known toxic effects  [3] .
 FOS are accepted in most countries as food ingredi-
ents that can be used without restrictions in food formu-
lations  [4] . FOS are low in calories and consumption is 
known to promote health of the intestinal tract. FOS re-
sist the hydrolysis of enzymes in the human digestive sys-
tem and are therefore able to reach the colon without be-
ing digested or metabolized. In the colon, FOS are com-
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 Abstract 
 Background: Yacon is a root crop which contains high 
amounts of fructooligosaccharides (FOS). The aim of this 
study was to investigate the effects of yacon syrup on colon 
transit time in healthy volunteers.  Methods: In a placebo-
controlled, double-blind study yacon was administered to 
16 healthy individuals (8 males, 8 females) in a dose of 20 g 
daily (equal to 6.4 g FOS) in a 2-week crossover design. Each 
period was interrupted by a 2-week wash-out phase. Transit 
time was assessed by a radio-opaque marker technique.  Re-
sults: Transit time (mean  8 SEM) through the gastrointesti-
nal tract was significantly decreased from 59.7  8 4.3 to 38.4 
 8 4.2 h (p  ! 0.001). Yacon was well tolerated with an excel-
lent side effect profile. Bloating is not an uncommon side 
effect observed with FOS, but bloating-related disturbances 
were not significantly more often reported with yacon com-
pared to placebo. Stool frequency increased from 1.1  8 0.1 
to 1.3  8 0.2 times per day and the consistency showed a 
tendency for softer stools as assessed by a numerical depict-
ed stool protocol. Neither parameter did, however, reach sta-
tistical significance.  Conclusion: Yacon markedly accelerates 
colonic transit in healthy individuals. Further studies are 
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pletely fermented  [5] to short fatty acids (e.g. butyrate, 
acetate propionate)  [6] . These effects can prevent and 
control constipation  [7] and make the FOS an interesting 
substance.
 Yacon syrup is a novel product, which contains up to 
50% FOS, made by concentrating the juice of the tuber-
ous storage roots of yacon. Production technology de-
pends on an evaporator, which is commonly used for the 
production of maple syrup. The physical and sensorial 
characteristics of yacon syrup are similar to those of hon-
ey, maple syrup or sugar cane syrup with the advantage 
of low caloric intake (even to be recommended for dia-
betics)  [8, 9] . However, clinical studies are required to 
substantiate the benefits of yacon consumption. To our 
knowledge, there have been no human placebo-con-
trolled studies that demonstrate the laxative effect of ya-
con. The aim of this study was therefore to investigate in 
healthy volunteers the effects of yacon syrup on gastroin-
testinal motility quantified by colon transit time mea-
surement. We hypothesized that yacon syrup would ac-
celerate colon transit time in comparison to placebo.
 Methods 
 The study was conducted as a randomized, placebo-controlled 
study at the University Hospital of Basel. The local ethical com-
mittee approved the protocol and all subjects gave written in-
formed consent. 16 healthy volunteers (8 females, 8 males) aged 
18–57 years of age (mean age of 29.3  8 4.9 years) were recruited 
for the study. Exclusion criteria were chronic constipation (less 
than 3 bowel movements per week and ROME criteria), diarrhea 
(more than 3 bowel movements per day), IBS symptoms accord-
ing to ROME II criteria, relevant concomitant cardiovascular, re-
nal, hematological, neurological, psychiatric, hepatological, in-
testinal disease including abdominal operation (exception appen-
dectomy) and pregnancy. Any kind of medication that could 
potentially influence bowel activity was prohibited (intake of lax-
atives and bran). Body size and weight had to be within normal 
ranges. For all females, a pregnancy test was obligatory. Physical 
activity was only allowed in moderate limits within individual 
habits.
 Study Design 
 The trial was conducted as a randomized, placebo-controlled, 
two-period, crossover study. Each period lasted for 2 weeks. In 
one period, subjects received 20 g placebo syrup (20 g molasses) 
per day, in the second period 20 g yacon syrup per day. The chem-
ical composition of the yacon syrup we used is shown in  table 1 . 
A pharmacist, who was not involved in the trial, prepared the 
bottles with the respective syrups. The two preparations were 
morphologically identical and delivered in brown containers to-
gether with a dosing cup of 20 ml, thereby making it possible to 
dose them in a double-blind fashion. The color, smell and taste of 
both syrups were similar: brown and sweet.
 The sequence of treatment was randomized. A washout period 
of 2 weeks was applied between two study periods. The primary 
endpoint of the study was the colonic transit time (CTT) using the 
radio-opaque marker technique. In brief, 10 radio-opaque mark-
ers were ingested on 6 consecutive days (from day 9 to day 14 of 
each period); 24 h after ingestion of the last set of markers, a plain 
abdominal X-ray picture was taken in the supine position. CTT 
was calculated as previously described  [10] . As secondary end-
points daily stool frequency, and stool consistency and side effects 
were assessed using questionnaires. For assessment of stool con-
sistency, a standardized stool protocol was used as depicted in 
 figure 1  [11] .
 Calculations and Statistics 
 Data are presented as mean  8 SD unless indicated otherwise. 
Transit times (segmental and total colonic transit) were compared 
between the treatment groups by analysis of variance using sex as 
a covariate. The level of significance was p = 0.05. Tests were per-
formed using SPSS for Windows v15.0.
 Results 
 Colonic Transit Time 
 The results on CTT are depicted in  table 2 and  fig-
ure 2 . Yacon treatment induced a marked acceleration of 
CTT, p  ! 0.001. The effect was mainly due to an accel-
eration of transit in the right colon. There was no signif-
icant effect of gender on transit time.
 Stool Parameters 
 Stool frequency with placebo averaged 1.1 (SD 4.2) 
bowel movements per day (range 0.6–2.4 bowel move-
ments per day), whereas stool consistency according to 
visual scoring ( fig. 1 ) averaged 2.7 (SD 0.7, range 1.5–4.0). 
Bloating measured as days with bloating was less than 1 
day out of 14 days with placebo treatment (mean 0.87, SD 
Table 1. Chemical composition of tested yacon syrup sample
Total carbohydrate, % 67
FOS, % 32
Simple sugars (glucose, fructose, sucrose), % 35
Protein, % 2.3
Fat, % 0.4
Ash, % 3.2
Water, % 29.5
Potassium, mg/kg 9,838.5
Sodium, mg/kg 830.38
Yacon syrup was prepared according to technical standards 
published [7].
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1.1; range 0–3). With yacon treatment, the mean stool fre-
quency was slightly, albeit nonsignificantly increased 
from 1.1 to 1.3 (range 0.6–2.4; p = 0.17), as was the stool 
consistency, which marginally increased from 2.7 to a 
value of 2.8 (range 1.7–4.1; p = 0.48). The mean number 
of days with bloating was not significantly different be-
tween the two groups (placebo 0.87, SD 1.1; yacon 0.6, SD 
1.0). The risk profile was excellent and no treatment-as-
sociated side effects were reported during the study.
 Discussion 
 The results of the present study can be summarized as 
follows: in this placebo-controlled crossover study, yacon 
syrup in a dose of 20 g daily (equal to 6.4 g FOS) induced 
a marked acceleration of CTT in healthy volunteers as as-
sessed by a radio-opaque marker technique. All subjects 
demonstrated a marked decrease in CTT. In addition, we 
observed a trend for slightly increased stool frequency 
and for softer stool consistency, although both parame-
ters did no reach statistical significance.
 Oligofructose is a dietary fiber with a potential for 
clinical application. FOS resists digestion by gastric acid 
and pancreatic enzymes in vivo. A key property of these 
fibers lies in the indigestibility of oligosaccharides, which 
gives rise to fermentation in the large intestine followed 
by an increase in Bifidobacteri and Lactobacilli. The pro-
cess results in an increased short-chain fatty acid produc-
tion (prebiotic effect). In 21 human subjects taking 6 g of 
FOS, the number of Bifidobacteri clearly increased with-
in a week  [12] . This property can induce several effects. 
First, normalization of stool frequency with an improve-
ment of constipation  [6, 13] has been reported, suggesting 
that FOS is acting as a laxative. Second, mineral absorp-
tion is increased, which leads to a rise in bone density 
 [14–16] . Third, an immunomodulatory effect and a po-
tential for cancer prevention have been postulated  [5] .
 Through the stimulation of bacterial growth and pro-
duction of short-chain fatty acids as a major product of 
bacterial fermentation, bowel habits are affected and FOS 
is acting as a laxative. A Taiwanese group conducted a 
controlled pilot study in 5 constipated subjects for twice 
30 days  [6] . In the 30-day period in which 10 g FOS was 
supplemented, defecation frequency, daily stool weight, 
and weight per individual stool were significantly aug-
mented. In addition, calcium and phosphate levels in 
Type 1 Separate hard lumps, like nuts
Type 2 Sausage-like but lumpy
Type 3 Like a sausage but with cracks in the surface
Type 4 Like a sausage or snake, smooth and soft
Type 5 Soft blobs with clear-cut edges
Type 7 Watery, no solid pieces
Type 6 Fluffy pieces with ragged edges, a mushy stool
 Fig. 1. Stool consistency as depicted by the Bristol Stool Form 
Scale  [11] . 
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 Fig. 2. Individual transit times during placebo versus yacon treat-
ment. CTT was markedly accelerated in all 16 subjects. 
Table 2. Effect of yacon on segmental and total transit time (h) in 
16 healthy volunteers
Placebo Yacon p value
Right colon 22.884.0 10.582.4 0.013
Left colon 24.082.9 20.383.1 NS
Sigmoid rectum 14.584.1 9.682.3 NS
Total CTT 59.784.3 38.484.2 0.001
Data are means 8 SEM.
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plasma were increased. The authors concluded that sup-
plementation of FOS was able to alleviate constipation in 
elderly men  [6] . In the present study, we can document 
that FOS in the form of yacon syrup accelerates colonic 
transit; the findings form the basis for a controlled clini-
cal evaluation of yacon in patients with constipation.
 Yacon was well tolerated in the present study in healthy 
subjects and no severe side effects were observed. FOS at 
high doses can increase flatulence and osmotic pressure 
and therefore cause intestinal discomfort  [3] . There was, 
however, no statistical difference in bloating scores be-
tween yacon treatment and control (molasses) in our 
study.
 Further studies in constipated patients are needed to 
confirm the data of this preliminary study in healthy 
 individuals. Dose-response relationships should be per-
formed in constipated subjects and a probably higher 
dose than 20 g yacon daily needs to be tested for a more 
potent action as a laxative. Because yacon syrup has a low 
caloric content, constipated obese persons or diabetics 
would be an ideal target group. Beside the laxative effect 
of yacon, other effects such as the probiotic, calcium ab-
sorptive, cholesterol- and triglyceride-reducing effects as 
shown in animal models  [13–16] should be investigated 
in human studies.
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